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Abstract 12 
Osteoarthritis (OA) is a highly prevalent condition and the hand is the most commonly affected site. 13 
Patients with hand OA frequently report symptoms of pain, functional limitations, and frustration in 14 
undertaking everyday activities. The condition presents clinically with changes to the bone, ligaments, 15 
cartilage and synovial tissue, which can be observed using radiography, ultrasonography or MRI. Hand OA is 16 
a heterogeneous disorder and is considered to be multifactorial in aetiology. This review provides an 17 
overview of the epidemiology, presentation and burden of hand OA, including an update on hand OA 18 
imaging (including the development of novel techniques), disease mechanisms and management. In 19 
particular, areas for which new evidence has substantially changed the way we understand, consider and 20 
treat hand OA are highlighted. For example, genetic studies, clinical trials and careful prospective imaging 21 
studies from the past 5 years are beginning to provide insights into the pathogenesis of hand OA that might 22 
uncover new therapeutic targets in disease. 23 
  24 
  25 
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[H1] Introduction  1 
Osteoarthritis (OA) is one of the leading causes of disability worldwide1. With the average age of 2 
populations increasing, the impact of OA and joint pain is set to rise 2. Disabling hand pain is a common 3 
complaint, affecting ~12% of individuals aged over 50 years in the UK general population3. For many of 4 
these individuals, this symptom can be ascribed to hand OA, which is the most common form of OA. Hand 5 
OA is a heterogeneous condition, often involving multiple joints 4, and can have distinct (but sometimes 6 
overlapping) patterns of joint involvement: for example, OA of the interphalangeal joints (IPJ) and/or the 7 
first carpometacarpal joint (CMCJ) 5. 8 
 9 
A gap exists between guidelines for the management of hand OA and current standards of treatment 6. 10 
Healthcare initiatives such as JIGSAW-E (Joint Implementation of Guidelines for oSteoArthritis in Western 11 
Europe; funded by EIT-Health) aim to close the evidence–practice gap for OA 7 by implementing 12 
international guidelines and quality standards 8,9. A common misconception is that OA of the hands effects 13 
the quality of life of individuals less than OA of the lower limbs, and many patients are encouraged to 14 
believe that hand OA is an inevitable result of ageing and that nothing can be done to improve the disease 15 
symptoms 10. These unfounded assumptions make prioritizing healthcare for hand OA a challenge. 16 
 17 
In this review, we provide an overview of the epidemiology, presentation and burden of hand OA and 18 
present areas where in the past 5 years new evidence has substantially changed the way we understand, 19 
consider and treat hand OA. We include updates on the imaging of hand OA and the development of novel 20 
imaging techniques, advances in knowledge of disease mechanisms, and the management of hand OA. 21 
 22 
[H1] Epidemiology  23 
[H2] Definitions of hand OA  24 
Hand OA can be defined in a number of ways: by the ACR clinical criteria 211, by structural changes 25 
determined by imaging (most frequently using plain radiography; so-called radiographic hand OA) and by 26 
radiographic changes accompanied by the presence of typical symptoms (pain, aching or stiffness; referred 27 
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to as symptomatic hand OA). For the latter two categories, a range of different definitions, particularly 1 
radiographic definitions Marshall 2008, have been used in the study of hand OA (Box 1). 2 
 3 
Radiographically, hand OA is characterized, as with other forms of OA, by joint space narrowing (JSN), 4 
osteophyte formation (which, for any joint, is pathognomonic of radiographic OA), subchondral sclerosis 5 
and subchondral cyst formation. Researchers have attempted to improve the detection of early disease 6 
features (including features that might not be evident by plain radiograph) by using MRI or 7 
ultrasonography; however, these techniques have not found a place in the diagnosis of hand OA in the 8 
clinic to date 12. 9 
 10 
[H2] Prevalence 11 
Hand OA is a highly prevalent condition with a well-recognized female preponderance that is particularly 12 
notable in patients with severe symptomatic disease presenting to secondary care 13, 14. Estimates of the 13 
prevalence of hand OA vary depending on the definition of hand OA used, as well as the age, sex and 14 
geographical area of the population studied, and can also be influenced by genetic factors, occupation and 15 
diet. Of the various hand OA definitions, radiographic hand OA is associated with the highest prevalence, 16 
ranging from 21% in a US population to 92% in a Japanese population 15, 16, 17. By contrast, the prevalence of 17 
symptomatic hand OA is much lower than radiographic hand OA, ranging from 3% in Iranian and Chinese 18 
populations to 16% in a US population 18, 19, 20. Prevalence estimates for hand OA are generally higher than 19 
those reported for hip and knee OA (hip OA: radiographic 1.0–45.0%, symptomatic 0.9–7.4%; knee OA: 20 
radiographic 7.1– 70.8%, symptomatic 5.4–24.2%) 15. The prevalence of hand OA is also higher in some 21 
groups of individuals, such as in patients with a HIV-1 infection, than in the general population 21. 22 
 23 
[H2] Incidence and progression 24 
The distinction between incidence (occurrence of the disease) and progression (development towards a 25 
more advanced stage of the disease) of hand OA is somewhat arbitrary and depends on the case definition 26 
of the disease used. With this caveat in mind, in one study of a USA population, the lifetime risk of 27 
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developing symptomatic hand OA in at least one hand by the age of 85 years was estimated at 40%, with 1 
47% of women and 25% of men developing the disease in this population 22. The annual incidence of hand 2 
OA varies between 0.2% and 4.7% for radiographic hand OA, and 0.1% and 1.1% for symptomatic hand OA 3 
irrespective of age, sex and geographical location 23, 24, 25 (Table 1). The incidence of hand OA peaks at the 4 
age of 50 in women and greatly exceeds the incidence measured for men at that age26. Progression of hand 5 
OA is usually slow, and only a small number of hand joints exhibit changes in each patient 24. The rates of 6 
radiographic progression vary from 3.2% to 23.5% per year depending on the population studied, the 7 
grading scale used and whether the definition of progression also incorporates incident OA (that is, new 8 
onset OA) (Table 2) 27,23.  9 
 10 
[H1] Disease presentation and burden 11 
[H2] Signs and symptoms 12 
OA is considered a condition of the whole joint, rather than just the articular cartilage, and signs and 13 
symptoms can arise from the cartilage, underlying bone, synovium, muscles, tendons and ligaments (or the 14 
sites of ligament insertion into the bone)29,30. Symptoms commonly include pain, stiffness and limitation or 15 
restriction of movement such as a decrease of grip and/or pinch strength. Signs of hand OA include ‘nodes’ 16 
of the affected IPJs (firm swellings over the superolateral and dorsal aspects of the distal interphalangeal 17 
joints (DIPJ) and proximal interphalangeal joints (PIPJ), known as Heberden and Bouchard nodes, 18 
respectively) and deformities such as squaring of the thumb base (Figure 1). Inflammation can produce 19 
redness, warmth, effusion and/or soft tissue swelling. 20 
 21 
Individuals with hand OA can be divided into different subgroups depending on the joints in the hands that 22 
are affected; these subgroups consist of nodal OA, first CMCJ OA and another presentation called erosive 23 
hand OA, in which the subchondral bone is affected by central erosions. First CMCJ OA is thought to occur 24 
most frequently, followed by nodal IPJ OA, a non-nodal form of IPJ OA and erosive hand OA5. However, 25 
apart from first CMCJ OA, which frequently occurs in isolation, there is considerable overlap in 26 
presentations among these subgroups, suggesting shared aetiologies 5.  27 
5 
 
 
 1 
[H3] First CMCJ OA  2 
Patients with first CMCJ OA have increased pain sensitivity, a reduced range of motion in thumb abduction 3 
and a decreased combined thumb abduction and index finger extension strength compared with healthy 4 
individuals 31. Notable associations between self-reported pain and function have been reported for these 5 
patients. Furthermore, compared with healthy individuals, patients with this condition have reduced grip 6 
and pinch strength 32, including a decrease in cylindrical grasp and key pinch strength that can begin in the 7 
early stages of disease 33,34. Some of these presentations might be due to changes in the structure and 8 
composition of the joint and changes in the innervation of the dorsal radial ligament, which has an 9 
important proprioceptive and stabilising role for the thumb base 35. In individuals with symptomatic first 10 
CMCJ OA, the presence of both ligament ruptures and dorsal subluxation is a common finding on MRI 36,37. 11 
The grind test (where the examiner exerts pressure whilst rotating the joint to test whether pain or crepitus 12 
are elicited) has frequently been used to determine the presence of first CMCJ OA 38. However, in a 2014 13 
study, the traction-shift (subluxation-relocation) test (where the examiner provokes subluxation and 14 
relocation of the joint passively to test whether pain is elicited) had a higher sensitivity, specificity and 15 
positive and negative predictive values for first CMCJ OA than the grind test 39. 16 
 17 
[H3] Nodal OA 18 
Nodes are the hallmark of nodal OA and most frequently affect the index finger DIPJ (Heberden nodes), 19 
followed by the thumb IPJ and the PIPJ (Bouchard nodes). The pattern of joints affected by nodes is similar 20 
to the pattern of joints affected by radiographic features 40 but although the presence of nodes is 21 
associated with underlying radiographic OA, IPJ OA can present with tenderness and bony enlargement 22 
without nodal involvement 41. Nodal OA occurs more often in women than in men and occurs most often in 23 
the dominant hand, suggesting the involvement of mechanical and hormonal factors 40. Patients with nodal 24 
OA frequently have synovitis, osteophytes, cartilage loss, and central and marginal erosions 42; aesthetic 25 
discomfort is also common 43. A strong positive association between the presence of nodes and 26 
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radiographic OA (in particular the occurrence of JSN) supports the notion that a clinical observation of 1 
nodes can be taken as an indication of hand OA without the need for radiographic assessment 40. 2 
 3 
[H3] Erosive hand OA  4 
The predominant features of erosive hand OA are central erosions and collapse of the subchondral bone. 5 
The term erosive OA is arguably a misnomer as central erosions are evident in many patients to some 6 
degree depending on the imaging modality used 44,45 ; hence, this condition probably represents an extreme 7 
phenotype of these changes. Although erosive hand OA is commonly considered a separate disease, 8 
increasing evidence suggest that this condition is a severe form of hand OA 46, 42,47. Erosive hand OA can 9 
affect the first CMCJ as well as the IPJs, but patients rarely have both erosive OA of the first CMCJ and IPJ 10 
(most patients have central erosions exclusively in one or the other) 48. Erosive OA of the IPJ occurs 11 
predominantly in women whereas erosive OA of the first CMCJ occurs more often in men than in women 48. 12 
Erosive hand OA has a higher clinical burden than non-erosive forms of hand OA and the associated 13 
disability might be as severe as that associated with rheumatoid arthritis (RA), depending on the setting 14 
49,50. 15 
 16 
Inflammatory changes, including synovitis and tenosynovitis (determined clinically as soft tissue swelling 17 
and by ultrasonography) and effusions and central and marginal erosions (determined by MRI), are 18 
frequently observed in patients with either erosive hand OA or nodal OA 42. The frequency and patterns of 19 
joints affected by erosive disease and severe non-erosive forms of hand OA are similar 46,47. However, 20 
progression of synovitis, joint effusion and radiographic OA occur more frequently in patients with erosive 21 
hand OA than in patients with non-erosive forms of hand OA (independently of the amount of synovitis and 22 
radiographic structural damage present at baseline) 51,52. Furthermore, the findings of a 2016 study 23 
indicated that patients with erosive hand OA had a higher level of inflammation (including a higher power 24 
Doppler activity, which is an indicator of the level of vascularization) than patients with non-erosive hand 25 
OA, suggesting that the inflammatory phenotype might differ in erosive and non-erosive forms of hand OA 26 
52. This concept requires further investigation. 27 
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 1 
[H2] Individual and societal burden  2 
The presence of hand OA frequently affects the ability of an individual to undertake everyday activities 53,54. 3 
Symptomatic hand OA is associated with poor self-reported general health, although the strength of this 4 
association varies by country and is often partially mediated by impaired physical hand function 55 . In a 5 
number of studies, the presence of hand OA and pain related to hand OA has been associated with 6 
atherosclerosis and cardiovascular disease 56,57,58,59,60. This association is analogous to the increased 7 
cardiovascular mortality observed in patients with painful OA of the large joints compared with the general 8 
population 61; this increased mortality is assumed to be caused by decreased load-bearing exercises but the 9 
association with hand OA suggests the involvement of other factors. Conversely, some data from the past 3 10 
years would indicate that individuals with hand OA have a similar risk of all-cause and cardiovascular 11 
disease-specific mortality to the general population 61,62.  12 
 13 
Patients with hand OA are frequently dissatisfied with the appearance of their hands, especially patients 14 
with Heberden and Bouchard nodes, joint deformity and/or erosive hand OA 43. Aesthetic dissatisfaction 15 
has negative effects on the patient symptoms, including increasing the level pain and stiffness and 16 
decreasing function of the hand; aesthetic dissatisfaction is also associated with depression, anxiety and 17 
negative perceptions by the patients about their illness 63,64,43. Patients with hand OA can have a distorted 18 
mental representation of pain in the hand, and normalisation of this distortion by multisensory illusions 19 
might offer pain relief 65.  20 
 21 
Although much is known about the economic burden of hand OA in terms of the direct costs of some 22 
treatments, less is known about the indirect costs of this condition such as loss of productivity 66,67,68. For 23 
example, in one study, arthroplasty surgery for first CMCJ OA often resulted in substantial time off work 69. 24 
Further research is required in this area.  25 
 26 
[H1] Imaging 27 
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[H2] Radiography 1 
For decades, radiography has been used to determine the presence and severity of hand OA, and to 2 
examine disease progression both in clinical and research settings including in randomised controlled trials 3 
(RCTs) 70, 71. This technology is widely available, inexpensive and is an acceptable procedure to patients. 4 
However, the inability to view non-bony structures (such as the joint capsule, synovium, ligaments and 5 
tendons and their entheseal attachment to the bone) using radiography and the insensitivity of this 6 
technique in detecting structural pathology limits its utility in both settings compared with other imaging 7 
modalities. For these reasons and as hand OA can often be reliably diagnosed on the basis of clinical 8 
presentations, EULAR and the National Institute for Health and Care Excellence (NICE) do not recommend 9 
imaging for the routine diagnosis of hand OA 72,8, although imaging might be useful in excluding other 10 
conditions 72,73. Routine imaging is not recommended for clinical monitoring unless there is an unexpected 11 
and rapid change in symptoms or clinical characteristics that suggest an alternative diagnoses such as RA or 12 
psoriatic arthritis (PsA 72).  13 
 14 
Radiography still has a place in the research setting; however, which scoring methods to use is still debated 15 
and might depend on the objective of the study and the population studied (for example, patients with 16 
erosive versus patients with non-erosive forms of hand OA) 74,75. Although radiography might have a low 17 
sensitivity in detecting features in early disease, the ability of this technique to detect hand OA progression 18 
over five years is similar to that of 1.0 Tesla MRI, although these imaging modalities do not always detect 19 
progression in the same joints 28. Given the lower cost of radiography compared with MRI, radiography is 20 
the suggested imaging modality of choice in observational studies with a long follow-up period 28. 21 
 22 
[H2] Advances in ultrasonography and MRI 23 
In the past 10 years, the use of ultrasonography and MRI for assessing patients with hand OA has increased, 24 
providing greater insight into the pathology of the disease and increased evidence that these imaging 25 
modalites have a higher sensitivity than radiography in determining the presence of pathological features 26 
such as osteophytes, JSN and central erosions 76,77,78,79,80,47. Using ultrasonography and MRI, researchers 27 
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have shown that inflammatory changes in the synovium and at the enthesis of the hands are a common 1 
finding in hand OA 81,82,83. Bone marrow lesions (BMLs) are also detectable in the hands by MRI (consistent 2 
with other joints affected by OA 83,84.  3 
 4 
Ultrasonography enables real-time multiplanar imaging at a relatively low cost. With this approach, 5 
inflammatory and structural changes can be observed without the use of ionising radiation or the need for 6 
a contrast agent; however, this technique is operator-dependent and bony structures such as cysts and 7 
BMLs cannot be detected. Several ultrasonography scoring systems for hand OA have been developed for 8 
grading pathological features as well as for use in research studies 85,86,79. On the basis of inter-observer and 9 
inter-reliability scores, the Outcome Measures in Rheumatology (OMERACT) group has endorsed the 10 
scoring of osteophytes using the Mathiessen atlas 12,79. However, although ultrasonography is reliable for 11 
determining healthy cartilage or a total loss of cartilage, the use of the ultrasonographic atlas for grading 12 
the severity of cartilage pathology is not supported 12,79. Ultrasonography findings have a good concordance 13 
with MRI findings 87,42, but the associations between ultrasonography findings and symptoms have differed 14 
across various studies 88,81,82,89,36.  15 
 16 
Although MRI is more expensive and takes a longer time to scan patients than other imaging modalities, 17 
this imaging modality is important in OA research (including in clinical trials) as it enables the visualisation 18 
of all joint structures through different pulse sequences in multiple planes 90. The Oslo hand OA MRI scoring 19 
system includes assessments of osteophytes, joint space narrowing, central erosions, cysts, BMLs, 20 
malalignment, collateral ligament pathology, synovitis, and flexor tenosynovitis in the DIPJ and PIPJ 91. This 21 
scoring system has a good intra-rater and inter-rater reliablity, has a good construct validity (in relation to 22 
joint tenderness) and has a higher sensitivity in determining the presence of osteophytes and erosions than 23 
radiography, computerised tomography (CT) or ultrasonography; however, this approach is time-24 
consuming because of the number of features and sites that require examination 91,80,92,93. In patients with 25 
erosive hand OA, , the presence of synovitis and BMLs has been assessed by the Oslo hand OA MRI scoring 26 
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system and has shown good intra- and inter-rater reliability and is associated with clinical symptoms, 1 
demonstrating a good construct validity 94.  2 
 3 
The Oslo hand OA MRI scoring system has been refined and the updated version, referred to as the 4 
HOAMRIS scoring system, includes measurements of the volume and extent of damage to the joint surface 5 
(to enable an improved assessment of central erosions compared with the Oslo hand MRI scoring system), 6 
excludes the assessment of collateral ligament pathology and flexor tenosynovitis, and combines the 7 
assessments of the proximal and distal joint surfaces (which were graded separately for the Oslo scoring 8 
system) for grading central erosions, cysts and BMLs 95. The HOAMRIS scoring system has a good inter-9 
reader reliability for cross-sectional readings but has a lower longitudinal reliability, which is thought to be 10 
because of the small range of change scores for many of the features. The responsiveness of this scoring 11 
system to change (as assessed by the standardised response means) at the patient level (that is, the sum 12 
scores for all DIPJ and PIPJ) is good for all assessed features, except for cysts and BMLs 96.  13 
 14 
A number of imaging features are associated with disease progression. For example, incident synovitis and 15 
BMLs determined on MRI are associated with incident joint tenderness after 5 years 97. Baseline MRI-16 
defined synovitis, BMLs and JSN predict radiographic progression in hand OA over 2 and 5 years 98,99. 17 
Baseline and persistent ultrasonography features including synovitis, joint effusion and power Doppler 18 
ultrasonographic activity in hand joints are associated with radiographic progression in the same joints 19 
after 2 and 5 years 100,101.  20 
 21 
Researchers have used ultrasonography to measure the treatment response of individuals with hand OA 22 
after intramuscular and intra-articular injections of steroid or other agents 102,103,36. However, understanding 23 
how inflammatory features in individual hand joints change over time is important to determine if 24 
ultrasound is a valid measure of assessing response to treatment. In a longitudinal study of patients with 25 
hand OA, inflammatory features that included synovial thickening, effusion or a power Doppler 26 
ultrasonography signal were consistently present in most patients over a 3 month period; however, in 27 
11 
 
 
individual joints, the inflammatory features changed over time, with persistent inflammatory features 1 
found in only 19% of the hand joints 104. Further investigation in other study populations and over different 2 
time periods is recommended before ultrasound is used as the primary outcome measure in assessing 3 
treatment response in individuals hand joints.  4 
 5 
[H2] Developments in Computerised Tomography  6 
CT enables more detailed visualisation of the bone structures than radiography, MRI or ultrasonography 7 
(albeit, this approach requires a high dose of ionizing radiation); hence, in the past few years this 8 
technology has been used for research purposes in hand OA. By using high-resolution peripheral 9 
quantitative computed tomography (HR-pQCT), a technique that is a based on CT but is able to achieve 10 
higher resolution images over a smaller field of view, researchers could show that new bone formation is 11 
more common at the cartilage-bone interface and joint margins in hand OA than in PsA 105. Additionally, 12 
disease-associated bone formation is located predominately on the palmar and dorsal sites in hand OA 13 
whereas PsA has more widespread involvement, suggesting that different mechanisms of aberrant bone 14 
formation occur in these two conditions 105. Findings from 3D CT imaging show that the curvature of the 15 
trapezial and first metacarpal articular surface of patients with early CMCJ OA differs from that of younger 16 
or older healthy individuals 106. Additionally, using MicroCT (radiographic imaging in 3D on a small scale), 17 
researchers have identified differences in the structure and configuration of the trapezium trabecular bone 18 
in individuals with and without first CMCJ OA 107. These findings indicate that morphological changes of the 19 
bones and joints can occur at the thumb base in hand OA. 20 
 21 
 [H2] Novel imaging methods in development  22 
Following the advancement of laser technology, a number of optical imaging modalities have been 23 
developed that might be applicable to hand OA 108 (Box 2), including diffuse optical tomography (DOT), 24 
fluorescence optical imaging (FOI) and optical coherence tomography (OCT) as well as related techniques 25 
such as photoacoustic imaging (PAI). These techniques offer low risk (non-ionising radiation) imaging, 26 
differentiation between the soft tissues in the hand and fast processing times 108. To date, these techniques 27 
12 
 
 
have been predominantly used for in vitro and ex vivo applications, whereas their use in vivo, particularly in 1 
patients with hand OA, is limited and is still undergoing development and testing 109. The use of systemic 2 
contrast agents for some of these applications might limit their use and acceptability to patients. 3 
 4 
[H2] Symptoms and structural pathology  5 
Discordance or weak associations between clinical symptoms and radiographic structural changes are 6 
frequently reported in OA and hand OA is no exception 110. However, it is possible that imaging modalities 7 
that are more sensitive than those currently in use could reveal stronger associations. In a 2015 systematic 8 
review of various cross-sectional studies, the researchers concluded that MRI-defined BMLs, osteophytes, 9 
bone attrition and cysts were not associated with hand pain severity 111. However, various MRI-defined 10 
features (such as moderate or severe synovitis, BMLs, central erosions, cartilage attrition and osteophytes), 11 
in addition to various ultrasonography-determined features (such as osteophytes, synovitis and the 12 
absence of joint cartilage), have been associated with tenderness in the same joints t 110,92,112. Furthermore, 13 
the cumulative effects of OA in multiple hand joints is associated with more severe hand pain 113, functional 14 
limitation 92 and weaker grip and pinch strength 114,92,17. Little is known about the course of symptoms in 15 
hand OA over time and how they relate to structural pathology. Inflammation (as determined by 16 
ultrasound) has been associated with the progression of radiographic hand OA and the subsequent 17 
development of bone erosions 115,116; however, further longitudinal research will enable a better 18 
understating of the disease processes and could help identify potential targets for treatment. 19 
 20 
[H1] Disease mechanisms  21 
Studying the pathogenesis of hand OA is difficult: researchers have limited access to diseased tissue, and 22 
for tissue that is available, the quantities obtained for molecular analysis are small. Healthy donor tissue (to 23 
use as a control) is rarely available, and no animal models of hand OA exist. In addition to the 24 
epidemiological and in depth prospective imaging studies detailed above, our understanding of hand OA 25 
disease pathways comes from a combination of genetic data analysis, and the outcomes (positive or 26 
negative) of clinical studies.  27 
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 1 
An important question to address is whether hand OA shares similar pathogenic pathways with OA at other 2 
joint sites. Of the common aetiological factors, perhaps the most important factor is abnormal mechanical 3 
loading. Although the joints of the hands are not weight-bearing, they are nonetheless load-bearing. 4 
Evidence for the involvement of mechanical loading in the development of hand OA is best demonstrated 5 
by the higher prevalence of OA in the dominant hand than in the non-dominant hand (80% of right-handed 6 
individuals with hand OA are predominately affected in their right hand) 117 and the lack of disease in the 7 
immobilized hand (for example, owing to hemiparesis or polio) of some patients with OA of the other hand 8 
118,119. Inflammatory changes in the entheses of the interphalangeal joints of patients with hand OA 9 
suggests that this tissue might be an important area of stress 120. Several features are unique to hand OA. 10 
For instance, unlike OA of the large joints, the incidence of hand OA peaks around the time of the 11 
menopause 26, the early inflammatory phase of disease seems to pre-date bone remodelling, and joint 12 
tenderness often seems to improve in individuals over time ( T.V.; unpublished data).  13 
 14 
[H2] Genetics of hand OA 15 
Genetic studies can provide powerful insights into pathogenesis. Hand OA has the highest estimated 16 
heritability of all types of OA (approximately 60%) 121. A comprehensive review published in 2008 17 
summarised all genetic studies in hand, hip, knee and spine OA, drawing from literature published up until 18 
2006 122. This study revealed just two candidate gene associations that had been replicated for hand OA: 19 
genetic variants in ACAN (encoding aggrecan, an integral component of the extracellular matrix in 20 
cartilagenous tissue) and HFE (encoding homeostatic iron regulator, a protein associated with 21 
hemochromatosis) 122. Since this study, five genome wide association studies (GWAS) 123,124,125,126,127 and 22 
numerous candidate gene studies have been published. For convenience gene candidates can be grouped 23 
into three areas according to their putative role in disease (Figure 2); those that are associated with growth 24 
factor signalling 124,125,128,129,130,131, those that contribute to the integrity and calcification of the extracellular 25 
matrix of cartilage 123,126,132,133,134,135,136, and those that relate to inflammatory pathways 127,137,138,139,140,141. 26 
Two GWAS in hand OA deserve further attention. The first was a study in Iceland in which two loci were 27 
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identified: one on chromosome 1, a rare variant associated with severe hand OA (no further allelic 1 
characterisation was given), and a second common set of variants on chromosome 15, all in ALDH1A2 127. 2 
ALDH1A2 encodes the enzyme retinal dehydrogenase 2 (ALDH1A2) that catalyses the synthesis of cellular 3 
retinoic acid. The polymorphic variants in ALDH1A2 are hypomorphic (that is, associated with lower levels 4 
of ALDH1A2 in hand OA cartilage 142. Retinoic acid is essential for forelimb development in the embryo and 5 
is a potentially interesting target as this metabolite has anti-inflammatory effects on many different cell 6 
types including chondrocytes 143. Paradoxically, chondrocyte biologists use retinoic acid to stimulate 7 
cartilage catabolism (albeit at supra-physiological levels 144.  8 
 9 
The second study, a 2017 GWAS from the Netherlands, identified a locus on chromosome 12, close to MGP 10 
126. This gene, also identified in a previous candidate gene study 134, encodes matrix Gla protein (MGP), 11 
which is responsible for preventing calcification of cartilage; the hypomorphic function associated with the 12 
risk variant might predispose individuals to abnormal chondrocalcinosis and altered biomechanical 13 
properties of the cartilage. MGP is known to be regulated by transforming growth factor beta (TGFβ), so it 14 
is of interest that candidate gene studies from the past few years have added further support for the 15 
association of hand OA with polymorphic variants in genes encoding TGFβ family members 137,133,132. These 16 
associations are consistent with the purported chondroprotective role of TGFβ in the joint. 17 
 18 
[H2] Sex hormones and hand OA  19 
All types of OA have a higher prevalence in post-menopausal women than in pre-menopausal women, but 20 
the relationship that hand OA has with the typical time of the menopause onset seems to be unique and 21 
robust 26,145. For instance, perimenopausal symptoms (such as hot flushes, irregular menstrual cycles) 22 
commonly occur at the time of presentation with hand OA 145. Whether this relationship is due to the loss 23 
of the established anti-inflammatory and pro-reparative effects of oestrogen or related to fluctuations in 24 
other sex hormones is currently unclear. Both oestrogen and testosterone regulate ALDH1A expression 146, 25 
and it is tempting to speculate that there might be important cross talk between retinoic acid and 26 
oestrogen signalling in the perimenopausal period.  27 
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 1 
[H2] Inflammation and hand OA 2 
The role of inflammation in hand OA remains particularly contentious. Although it is widely accepted that 3 
inflammatory changes (including clinical and imaging-based synovitis) occur in disease, these changes are 4 
typically relatively modest in hand OA compared with inflammatory arthritides such as RA147, and the 5 
pathogenic role of inflammation is far from certain. Data from prospective imaging studies show that 6 
baseline synovitis on MRI or ultrasonography predicts radiographic progression and central erosion, 7 
respectively 99, 148,116,115. However, it is worth bearing in mind that the presence of bone marrow lesions and 8 
joint space narrowing also predict progressive disease 99, so it is possible that inflammation is a 9 
consequence rather than cause of progressive disease.  10 
 11 
A wide range of OA serum or plasma biomarkers have been investigated in hand OA, which can provide 12 
insight into disease development. These biomarkers include various inflammatory markers, such as C-13 
reactive protein and adipokines, and markers of cartilage or bone homeostasis, such as type II collagen 14 
149,150. In one small sub-study of 18 patients from a 2016 hand OA clinical trial, serum IL-1 levels were 15 
associated with loss of hand function and radiological erosions 151. Although erosive and non-erosive hand 16 
OA seem to have different biomarker profiles, to date biomarker characterization remains less developed 17 
for hand OA than it is for OA at other sites such as the knee. Currently there are no validated serum or 18 
plasma biomarkers for diagnosing hand OA, stratifying its severity, predicting its progression or response to 19 
treatment. 20 
 21 
Results from clinical trials can also aid in the understanding of disease pathogenesis. Intra-articular steroid 22 
therapy is routinely used in many cases to treat symptomatic hand OA. A 2015 randomised controlled study 23 
of 60 patients with symptomatic hand OA showed that steroid (triamcinolone) injection in combination 24 
with lidocaine (a local anaesthetic) resulted in a statistically significant improvement in the patients hands, 25 
in terms of pain on movement and physician’s assessment of swelling, compared with treatment with 26 
lidocaine alone 152. Interestingly, lidocaine injection alone resulted in a striking response in the patients in 27 
16 
 
 
this study and five secondary disease activity measures did not differ between the two groups. The 1 
emphasis on targeting inflammation in hand OA has been further unsettled by the negative results of 2 
several randomised controlled studies in hand OA using traditional anti-inflammatory or ‘anti-synovial’ 3 
agents. These findings include a failure to demonstrate a difference between placebo treatment and 4 
treatment with hydroxychloroquine 153,154, anti-TNF agents 155,156 or IL-1 targeting strategies 157.  5 
 6 
[H1] Advances in therapy  7 
The management of hand OA combines both non-pharmacological and pharmacological approaches. 8 
Surgical treatments are offered to those with severe symptoms and for whom conservative approaches 9 
have failed 29. In this section we describe findings from original studies produced within the past five years 10 
for core recommendations (a range of self-management support), first line analgesia and novel 11 
pharmacological targets.  12 
 13 
[H2] Non-pharmacological therapies  14 
In a 2017 systemic review, Lue and colleagues 158 provided an update on an earlier review of non-surgical 15 
therapies for hand OA Mahendira 2009 and the reader is directed to this manuscript for an appraisal of the 16 
quality of some of the studies discussed below. In this section, a summary of the core and adjunctive 17 
treatments and surgery are briefly provided. 18 
 19 
[H3] Core Interventions: self-management support 20 
Self-management programmes for hand OA can include a range of approaches such as providing the 21 
patient with written information on hand OA and self-management approaches, giving advice on hand 22 
exercises and joint education (such as joint protection strategies and pacing of activities), weight 23 
management strategies, and using new models of care 159,160. For example, Moe et al.160 concluded that the 24 
use of an integrated, multidisciplinary care model, although not superior in clinical outcomes, resulted in 25 
greater patient-reported satisfaction compared with usual care.  26 
 27 
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Written information on the underlying disease and self-management approaches, such as the OA 1 
guidebook 161, are an essential component of the core management of hand OA, although limited evidence 2 
is available for the effectiveness of hand OA education alone. In the trial that tested a OA consultation 3 
model (which consisted of an OA guidebook, an OA consultation with a GP, and a subsequent follow up 4 
with a practice nurse in a dedicated OA clinic), the supply of written information by general practitioners 5 
and practice nurses to patients increased from 4% to 28% in the model OA consultation arm, whereas no 6 
changes from baseline were observed in the control arm (which consisted of usual care alongside a 7 
resource pack of written advice for patients) 162. Although implementation of this model did not improve 8 
the health status of patients, it did improve the implementation of clinical guidelines (the NICE OA 9 
recommendations) by clinicians and allied health professionals, along with the use of self-management 10 
approaches159. 11 
 12 
Education on maintaining joint health is often described as ‘joint protection education’ or ‘joint education’. 13 
In the SMOotH (Self-management of Osteoarthritis of the Hand) study, which included community dwelling 14 
adults (aged 50 years and over) with ACR-defined hand OA, the individuals who attended occupational 15 
therapy classes for joint protection education (using written patient information from a Arthritis Research 16 
UK booklet 163) were twice as likely to respond to treatment than those did not attend the classes164. 17 
 18 
Several trials of hand exercise for hand OA 165,166,167 have been published in the past few years, along with a 19 
Cochrane systematic review 168. Exercise is recognised as an effective analgesic therapy for those with OA at 20 
any site 169. However, despite continued efforts to identify the specific benefits of exercises for hand OA, 21 
the Cochrane review 168 found that the magnitude of the benefit of exercise and which exercises should be 22 
prescribed are still uncertain. For complex interventions, blinding the therapist or patient to the 23 
intervention is difficult, and in large studies, self-report questionnaires are often used, which contribute to 24 
a low quality rating of the study when assessed in systematic reviews. The findings suggest that 25 
recommending one approach to exercise over another is not possible at present for hand OA. Few studies 26 
have investigated the cost effectiveness of exercise in the management of hand OA but findings from the 27 
18 
 
 
SMOotH study show that hand exercises, delivered in classes by occupational therapists, could be a cost 1 
effective approach over 12 months 66. 2 
 3 
The association of obesity and hand OA is continually debated 170,171. Weight management forms part of an 4 
holistic approach to managing OA in general and as hand OA often co-exists with OA in other sites, 5 
consultations for hand OA provide an opportunity to offer weight management advice and referral to 6 
services if a patient is overweight, as recommended by NICE quality standards 8,9.  7 
 8 
[H3] Adjunctive conservative therapies 9 
Several systematic reviews have been published in the past few years on the use of non-surgical treatments 10 
for first CMCJ OA 172,173. Local treatments such as splints (pre-fabricated or custom orthotics worn on the 11 
affected joint) might offer warmth, support and stabilisation of joints that are normally painful on 12 
movement. However, there continues to be uncertainty about the exact mechanism of action of splints, 13 
and their optimal design and instructions for use to maximise adherence and safety. Soft splints, off the 14 
shelf splints and splints worn at night time might be more acceptable to patients than hard splints, custom 15 
made splints, or splints to be worn during the day 174,175,176. 16 
 17 
Researchers have investigated splints or orthoses for first CMCJ OA 177,178,179,180,181 or IPJ OA 182,173,172,158 as 18 
well as pressure gloves for hand arthritis 183. However, currently, what type of splint is best is unclear and 19 
data are inconsistent as to whether splints provide symptom relief in the hand 158. The use of splints does 20 
improve function and pinch strength in patients with first CMCJ OA 172,173. Most studies of splinting have a 21 
high risk of bias because of difficulties in establishing or maintaining participant blinding or including true 22 
sham devices, but the inclusion of a placebo splint in new upcoming studies such as the OA of the thumb 23 
therapy (OTTER) trial gives an opportunity to address some of the key limitations of previous trials of 24 
splinting 174,175,176.  25 
 26 
[H3] Other non-pharmacological therapies 27 
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Several other therapies that have been tested for the treatment of hand OA include Spa therapy 184, joint 1 
mobilisation 185, taping Wade 2018 , and ultrasound therapy 186. Although evidence is limited for the efficacy of 2 
such treatments, these approaches have been recommended in various clinical guidelines for the 3 
management of hand OA such as the EULAR Hand OA recommendations 29,187, 188. 4 
 5 
[H2] Pharmacological therapies 6 
[H3] First line analgesia: topical treatments  7 
Topical NSAIDs are recommended in international and national guidelines as a first line pharmacological 8 
treatment option for symptomatic hand OA (owing to the superior safety profile to oral analgesics 8, 187 and 9 
improved efficacy compared with oral paracatamol 189 and placebo 190). Overall, topical NSAIDs are superior 10 
to placebo for relieving pain and improving function in OA 189. Although salicylate gel is associated with 11 
higher withdrawal rates owing to adverse events, the remaining topical NSAIDs are not associated with any 12 
increased local or systemic adverse events 190. The benefits of topical NSAIDS have been summarised 13 
elsewhere 191 but there is still uncertainty over the relative efficacy of topical NSAIDs compared with the 14 
efficacy of other topical treatments such as capsaicin. 15 
 16 
Topical capsaicin, an extract of hot chilli pepper, is recommended for the treatment of OA pain 8 but studies 17 
of this treatment in hand OA are limited. In a 2014 systematic review 192 of RCTs of topical capsaicin use 18 
in OA, which included five double-blind RCTs and one case-crossover trial, only one study included patients 19 
with hand OA. Capsaicin was reported to be safe and well-tolerated across all the included studies, with no 20 
evidence of systemic toxicity; however, there was evidence that this treatment could exacerbate 21 
inflammatory symptoms. Capsaicin might therefore be more suited to patients who lack inflammatory signs 22 
and have persistent pain or neuropathic symptoms, which aligns with the use of capsaicin for neuropathic 23 
pain associated with other conditions. This treatment is associated with mild burning at the application site, 24 
which peaks after one week and declines over time 192. Capsaicin treatment efficacy warrants further 25 
investigation. 26 
 27 
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[H3] Local analgesia 1 
 Injecting drugs such as glucocortiocoids directly into the joints provide local symptomatic relief and offers 2 
another option in addition to core treatment. Interest in the use of intra-articular injection therapy in hand 3 
OA continues 193,152,194,195,196,197, as this approach is preferable to surgical approaches in elderly patients with 4 
comorbidities 197.  5 
 6 
The benefits and harms of intra-articular therapies were assessed in a 2016 systematic literature review 7 
and meta-analysis; this analysis included trials that investigated the efficacy or safety of any intra-articular 8 
therapy in first CMCJ and IPJ OA compared with placebo or other treatments for which pain was the main 9 
outcome 197. A total of 13 trials (including 864 patients with hand OA; 11 trials of patients with OA of the first CMCJ 10 
and 2 trials of patients with OA of the IPJs) were included. The results of a meta-analysis of two trials comparing intra-11 
articular corticosteroids and placebo treatment in patients with first CMCJ OA indicated that intra-articular 12 
corticosteroid resulted in no improvement in pain. Synthetic hyaluronan also seemed inefficacious compared with 13 
placebo in patients with first CMCJ OA. However, in one trial of patients with OA of the IPJ, the patients receiving 14 
corticosteroids had considerable improvements in pain during movement compared with the patients receiving 15 
placebo 152. The authors of the systematic review 197 concluded that intra-articular injection of corticosteroids or 16 
hyaluronan do not seem more effective than placebo in first CMCJ OA. However, the placebo response can be large 17 
and intra-articular use in combination with other modalities such as splinting might be a relevant option.  18 
 19 
[H3] Adjunctive analgesia  20 
Paracetamol is prescribed for hand OA if topical treatments are ineffective or not tolerated 8, although the 21 
effect size of this therapy in the treatment of large joint OA might be smaller than previously thought 189. If 22 
ineffective, and following careful assessment of the risks and benefits to the individual, oral NSAIDS (such 23 
as naproxen), cyclooxygenase (COX)-II inhibitors or opiates might be introduced. These drugs should 24 
generally be used sparingly and only when required to limit the risk of toxicity. A proton pump inhibitor 25 
should be prescribed along with NSAIDs to protect against NSAID-induced gastrointestinal adverse events 26 
198. In a 2015 study of patients with first CMCJ OA 199, in the small number of participants included in the 27 
21 
 
 
final analysis (n=19), the patients receiving naproxen had a considerable reduction in brain activity in areas 1 
commonly associated with pain perception compared with those patients receiving placebo. 2 
 3 
The use of several novel agents have been investigated for the treatment of hand OA and typically involve 4 
the re-purposing of disease modifying anti-rheumatic drugs or biologic therapies licensed for use in RA: 5 
these therapies include adalimumab, a monoclonal antibody to TNF 155, hydroxychloroquine 154, doxycycline 6 
200 and GCSB-5, a herb extract 201. Evidence from these studies suggest that adalimumab and 7 
hydroxychloroquine are not effective in treating hand OA pain 155,154. Further studies are much needed to 8 
identify oral treatments that improve hand pain or modify the course of disease. A number of drug trials in 9 
OA, including ongoing trials, might be relevant to hand OA and have been reviewed elsewhere 202. The 10 
ongoing clinical trials include drugs that inhibit inflammatory mechanisms (such as GM-CSF 203 and anti-IL-6 11 
204) but novel targets relevant to other OA mechanisms might be needed to move the field forward.  12 
 13 
Nutraceuticals are not recommended by NICE for the management of OA, but researchers have 14 
investigated their effects in hand OA. In a systematic review of oral chondroitin for OA, including hand OA, 15 
chondroitin treatment (alone or in combination with glucosamine) was associated with a short-term 16 
benefit in terms of pain relief compared with placebo (albeit most of the studies assessed were of low 17 
quality) 205. The low risks associated with chondroitin might account for its popularity as an over-the-18 
counter supplement in individuals with hand OA, but more evidence is needed to advocate the use of this 19 
supplement in routine clinical practice.  20 
 21 
[H3] Surgery  22 
Surgery in hand OA is recommended for patients who are refractory to non-surgical management 8. In a 23 
survey of 163 patients with first CMCJ OA, the results confirmed that patients predominantly 24 
visit hand surgeons seeking treatment to reduce pain, and that improvements in function and aesthetic 25 
image are a lower priority for these patients 206. The findings highlight the need to elicit patients' 26 
expectations before treatment and to discuss potential treatment outcomes in order to achieve optimal 27 
22 
 
 
gain from surgery. Placebo-controlled RCTs for many surgical procedures carried out for the treatment of 1 
hand OA are lacking. 2 
 3 
[H1] Guidelines and implementation  4 
Guidelines have previously been published that address the clinical management of hand OA 207,208,8,29, 5 
including the newly released 2018 update from EULAR 209. However ensuring the uptake of guidelines in 6 
clinical practice is challenging 159, 162 . Improvements are needed in ways of recording hand OA diagnosis in 7 
primary care and evaluating the quality of hand OA care, including the implementation of guidelines. 8 
Demonstrating an association between the implementation of clinical guidelines and improvements in the 9 
health status and function of patients is difficult in real world settings 159. This field of investigation is 10 
growing; for example, ways in which to measure the quality of care that include valid quality indicators and 11 
demonstrate the effects of implementation are now high on the research agenda.  12 
 13 
Regarding research guidelines, a preliminary core set of outcomes has been developed by OMERACT using 14 
Delphi exercises and systematic literature review 210. In clinical trials of symptom modification, the 15 
minimum outcomes should include assessments of pain, physical function, global patient assessment, joint 16 
activity and hand strength. For clinical trials examining structure modification as well as observational 17 
studies, structural damage should also be examined 210. Finally, guidelines on imaging in hand OA clinical 18 
trials are also available 71.  19 
 20 
[H1] Conclusion 21 
Hand OA is a common, disabling, heterogeneous condition. Studies in the past few years have provided 22 
some advances in our understanding of the burden and underlying mechanisms of hand OA as well as in 23 
hand OA therapy, but there is much still to understand. Localised therapies for hand OA such as hand 24 
exercises and topical treatments offer small but clinically important amounts of symptomatic relief in hand 25 
OA and should arguably be more widely used. Hydroxychloroquine, previously used anecdotally off-label to 26 
treat severe forms of the disease, is now known to be an ineffective in the treatment of established 27 
23 
 
 
symptomatic radiographic hand OA and should not be used in such patients. The lack of efficacy of many 1 
anti-rheumatic drugs in hand OA has catalysed a re-evaluation of potential disease targets. The 2 
disappointing results from clinical trials reaffirm the need for a better understanding of basic underlying 3 
disease mechanisms, and arguably a better method for identifying and stratifying patient with early disease 4 
and/or who have at high risk of progression, at a time when diseases processes might be susceptible to 5 
intervention.  6 
 7 
In primary care management, the diagnosis of hand OA without the use of imaging is still recommended by 8 
international guidelines 8. A better approach for classifying and coding the disease is needed. Such an 9 
approach is essential for improving the delivery of quality care for this common condition. Guidelines such 10 
as the newly updated 2018 EULAR recommendations209 for the management of hand OA will continue to 11 
improve the quality of care for patients with hand OA, provided that steps are taken to accelerate the 12 
implementation of such guidance into every day practice. 13 
 14 
  15 
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Key points  
 Hand osteoarthritis (OA) is highly prevalent and individuals with this condition frequently report 
symptoms of pain, functional limitations, and frustration in undertaking everyday activities. 
 Clinical imaging is not recommended for the diagnosis or routine monitoring of patients with hand 
OA unless an alternative diagnosis is suspected. 
 MRI and ultrasonography findings have provided insight into hand OA pathology, but further 
prospective studies are required to inform on how features of the disease change over time. 
 Hand OA is multifactorial in aetiology with evidence for the involvement of abnormal mechanical 
loading and hereditary factors whereas the contribution of inflammation to pathogenesis remains 
contentious. 
 Recommendations for core treatments in the management of hand OA should be integrated into 
clinical practice to improve the quality of care for patients. 
 A greater understanding of the presentation, pathogenesis and disease course is needed to help 
provide targeted therapy with existing and new treatments . 
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Review criteria  
The aim of this review is to update earlier reviews published in Nature Reviews Rheumatoloy(Kloppenburg-
2014,Kloppenburg-2011) with evidence from a search over the past 5 years for new original studies, Cochrane 
reviews and International Guidelines. 
A search for original articles that examined hand osteoarthritis and were published between 1st Jan 2012 to 
10th Oct 2017 was performed in MEDLINE. The title and abstracts were searched using the following terms: 
“osteoarthr$ OR OA” AND “hand OR finger OR thumb OR interphalangeal OR inter phalangeal OR IPJ OR 
metacarpophalangeal OR metacarpo phalangeal OR MCP OR carpometacarpal OR carpo metacarpal OR 
CMC OR trapezioscaphoid OR trapezio scaphoid OR TS OR erosive OR nodal OR node”. All full-text papers 
and articles in the English-language were reviewed. We also searched the reference lists of identified 
articles for further relevant papers. 
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Box 1. Commonly used definitions of hand OA by category  
 
Clinical 
 ACR hand osteoarthritis (OA) criteria 211: hand pain, aching or stiffness and 3 of the following four criteria: 
- Hard tissue enlargement of 2 or more of 10 selected joints* 
- Hard tissue enlargement of 2 or more distal interphalangeal joints (DIPJ) 
- Fewer than 3 swollen metacarpophalangeal joints (MCPJ) 
- Deformity of at least 1 of 10 selected joints* 
 (As used in REF 212, REF 213, REF 75, REF 214 and REF 55) 
Radiographic 
 Kellgren–Lawrence 215,216 grade 2 or greater in at least one hand joint (As used in REF 217; REF 25; REF 246; 
REF 218; REF 219; REF 220; REF 221; REF 20; REF 75; REF 21) 
 Kellgren–Lawrence grade 2 or greater in at least two hand joints (As used in REF 222 and REF 223) 
 Kellgren–Lawrence grade 2 or greater in two of three groups of hand joints (DIPJs; proximal 
interphalangeal joints (PIPJs); first carpometacarpal joint (CMCJ) and/or scaphotrapezial joint (STJ)) (As 
used in REF 224, REF 225; REF 226) 
 Altman altas score 44 of 1 or more for osteophytes or joint space narrowing in one or more hand joints (As 
used in REF 227; REF 228; REF 229) 
 
Symptomatic  
 Hand pain, aching or stiffness and the presence of at least one hand joint with a Kellgren–Lawrence grade 
2 or greater (As used in REF 230; REF 19; REF 20) 
 Hand pain, aching or stiffness and the presence of with a Kellgren–Lawrence grade 2 or greater in the 
same joint, with at least one hand joint affected (As used in REF 25) 
 Hand joint symptoms and the presence of at least one hand joint with radiographic OA in the same hand 
(As used in REF 22) 
 
*The 10 selected joints refers to the second and third DIPJ, the second and third PIPJ and the CMCJ of both hands  
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Box 2. Novel and alternative imaging methods in development applicable to hand OA  
  
Diffuse optical tomography (DOT) and Photoacoustic imaging (PAI) 
 In DOT, light from the near infra-red spectral region is passed through tissues and the spatial and 
temporal variation in light absorption and scattering is measured and used to construct tomographic 
images 231. Using 3D DOT, researchers could distinguish between distal interphalangeal joints (DIPJ) 
affected by osteoarthritis (OA) and healthy joints 232. After further methodological refinements, this 
technique could distinguish between patients with hand OA and patients with psoriatic arthritis or 
healthy individuals 233. Incorporating PAI with DOT improves the image resolution enabling better 
differentiation of bone from soft tissue 234. 
Fluorescence optical imaging (FOI) 
 In FOI, tissues are illuminated with a light source that can range from ultraviolet to infra-red; this light 
excites fluorophores that have been introduced through a fluorescence contrast media that 
accumulates at sites of inflammation 235,236. In one study investigating the use of FOI in OA, which 
looked at joints of the hand, the researchers noted that although similar proportions of individuals with 
inflammation were distinguished using FOI and grey-scale or power Doppler ultrasonography in 
patients with either OA or rheumatoid arthritis, a particular phase of fluorescence dye flooding in FOI 
(phase 2) FOI might be more informative in OA 237 . 
 
Optical coherence tomography (OCT) 
 OCT employs light from the infra-red end of the spectrum, which is passed through the tissues under 
investigation and the resulting reflections are measured and cross-sectional images produced. OCT can be 
used to visualise cartilage in the first carpometacarpal joint (CMCJ) and detect early changes including 
thickening of the cartilage and changes to the articular surface that are consistent with histology findings 
238. Additionally, overlaying the OCT images onto CT images can help with the visualisation of cartilage 238.  
 
Trabecular bone texture  
 The texture of trabecular bone is quantifiable and changes in bone texture are observable in early OA at 
the knee 239, 240. Work using directional fractal signals has now extended this finding to the smaller regions 
of the hands, and the use of augmented variance orientation transform (AVOT) has the potential to be 
useful in the early detection and prediction of hand OA 241. 
 
Positron emission mammography (PEM) 
 PEM is a nuclear medicine modality that has been used to detect or characterize breast cancer. The 
PEM scanner has a small field of view but is comparable to a standard Positron Emission Tomography 
(PET) or CT scan for evaluating hand OA 242.  
 
Photographic  
 A system for scoring hand OA from photographs offers an alternative method of diagnosing hand OA to 
a clinical or radiographic assessment and is a commonly used, reliable and valid method of scoring 
hand OA 243,244. It offers researchers a feasible alternative method of data collection, which might be of 
particular use for large population-based studies, or studies covering wide geographic or remote areas. 
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Figure 1. Features of hand OA  
 
Photographic image of an individual’s hand showing squaring of the thumb base and bony enlargement, 
nodes and deformity of the interphalangeal joints, and the corresponding radiograph displaying 
osteophytes, joint space narrowing and subchondral sclerosis at the thumb base and interphalangeal joints  
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Figure 2. Predicted molecular drivers of hand OA by genetic association 
 
Mechanical load is central to the pathogenesis of hand OA and influences growth factor bioavailability, 
inflammation and matrix degradation. The genes shown in this figure have been linked to radiographic or 
symptomatic hand OA in at least one study (some of which have not been replicated). *Genetic 
associations that were identified by genome wide scans (the other associations were identified using 
candidate gene approaches).  
 
 
 
Extracellular signal-regulated kinase, ERK; phosphoinositide 3-kinase 
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Table 1. Reported incident rates for hand OA  
Study  Population Number of 
participants 
 
Incidence Follow-up time 
period 
Annual 
incidence  
Radiographic hand OA 
Haugen et 
al. (2017)24  
OAI (study 
cohort), USA 
407 
 
18.9% 4 years 4.7% 
Haugen et  
 
Framingham, 
USA 
810 Women: 34.6%  
Men: 33.7%  
Median 8.7 (IQR 
7.9-9.5) years 
Women: 4.0%  
Men: 3.9%  
Paradowski 
et al. 
(2010)245 
Lund, Sweden 97 14.4% Mean 9.6 (SD 
0.4) years 
1.5% 
Chaisson et 
al. (1997)246 
Framingham, 
USA 
458 Overall: 83%  
Women: 87%  
Men: 76%  
24 years Overall: 3.5% 
Women: 3.6%  
Men: 3.2%  
Bagge et al. 
(1992)247 
Goteborg, 
Sweden 
74 DIPJ: 13.6% 
PIPJ: 13.6% 
First CMCJ: 4.9% 
4 years DIPJ: 3.4% 
PIPJ: 3.4%  
First CMCJ: 1.2%  
Kallman et 
al. (1990)23 
BLSA (study 
cohort), USA 
84 Individuals aged <40 
years: 56/1000 person 
years 
Individuals aged 40-59 
years: 69/1000 person 
years 
Individuals aged ≥60 
years: 106/1000 person 
years  
Age <60: mean 
23.5 (SEM 
±0.25) years; 
Age ≥60: mean 
16.9 (SEM 
±0.45) 
Individuals aged 
≤40 years: 0.2% 
Individuals aged 
40-59 years: 
0.3%; 
Individuals aged 
≥60 years: 0.6%  
Plato et al. 
(1979)248 
BLSA (study 
cohort), USA 
65 47.7%  Mean 13.45 
(range 12-16) 
years 
3.5% 
Symptomatic hand OA 
Haugen et 
al. (2011)20  
Framingham, 
USA 
810 Women: 9.7%  
Men: 4.0%  
Median 8.7 (IQR 
7.9-9.5) years 
Women: 1.1% 
Men: 0.5%  
Oliveria et 
al. (1995)25 
Massachusetts, 
USA 
~130,000 100/100,000 person 
years 
1 year 0.1% 
Clinical diagnosis of hand OA* 
Yu et al. 
(2015)249  
CIPCA 
(database), UK 
94,955 1.3% 1 year 1.3% 
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* Consultation rate for clinical diagnosis 
OAI, Osteoarthritis Initiative; DIPJ, Distal Interphalangeal Joints; PIPJ, Proximal Interphalangeal Joints; CMCJ, Carpometacarpal Joints; IQR, 
Interquartile range; SD, Standard deviation; BLSA, Baltimore Longitundinal Study of Ageing; SEM, Standard error of the mean; CIPCA, 
Consultations in Primary Care Archive; SIDIAP, Sistema d’Informació per al Desenvolupament de la Investigació en Atenció Primària. 
 
  
Prieto-
Alhambra et 
al. (2014)26 
SIDIAP 
(database), 
Spain 
3,266,826 2.4/1000 person years Median 4.45 
(IQR 4.19-4.98) 
years 
0.1% 
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Table 2. Reported progression rates for hand OA  
 
Study Population Number of participants Progression Follow-
up 
time 
period 
Annual progression 
rate 
Radiographic definition (with incorporation of incidence rate) 
Haugen et al. 
(2017)24  
OAI (study 
cohort), USA 
994 
 
59.4% 4 years 14.9% 
Haugen et al. 
(2017)28  
Oslo, 
Norway 
69 
 
62.3% Mean 
4.7 (SD 
0.4) 
years 
13.3% 
 Bijsterbosch et al. 
(2014)250 and 
Bijsterbosch et al. 
(2011)  
GARP (study 
cohort), 
Netherlands 
236 
 
Overall: 52.5% 
Osteophyte 
progression: 
44.9% 
JSN 
progression: 
25.8% 
Mean 
6.1 
(range 
5.0-
7.8) 
years 
Overall: 8.6% 
Osteophyte 
progression: 7.4% 
JSN progression: 
4.2% 
Bijsterbosch et al. 
(2013)132 
GARP (study 
cohort), 
Netherlands 
161 
 
Overall: 60% 
Osteophyte 
progression: 
53% 
JSN 
progression: 
32% 
6 years Overall: 10% 
Osteophyte 
progression: 8.8%  
JSN progression: 
5.3% 
Bijsterbosch et al. 
(2013) 132 
GARP (study 
cohort), 
Netherlands 
128 
 
Overall: 39% 
Osteophyte 
progression: 
24% 
JSN 
progression: 
29%  
2 years Overall: 19.5% 
Osteophyte 
progression: 12% 
JSN progression: 
14.5%  
Paradowski et al. 
(2013)251 and 
Paradowski et al. 
(2010)245 
Lund, 
Sweden 
118 
 
59.3% Mean 
9.6 (SD 
0.4) 
years 
6.2% 
Yusuf et al. 
(2011)252  
GARP (study 
cohort), 
Netherlands  
164 
 
33.5%  Mean 
6.0 (SD 
0.6)  
5.6%  
Botha-Scheepers 
et al. (2009)253 
GARP (study 
cohort), 
Netherlands 
172 
 
Osteophyte 
progression: 
21.5%  
2 years Osteophyte 
progression: 10.8% 
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JSN 
progression: 
19.2%  
JSN progression: 
9.6%  
Botha-Scheepers 
et al. (2007)27 
GARP (study 
cohort), 
Netherlands 
184 
 
Osteophyte 
progression: 
47% 
(probands) 
and 42% 
(siblings) 
JSN 
progression: 
34% 
(probands) 
and 37% 
(siblings)  
 
2 years Osteophyte 
progression: 23.5% 
(probands) and 21% 
(siblings) 
JSN progression: 17% 
(probands) and 
18.5% (siblings) 
Cvijetić et al. 
(2004)254 
Croatia 186 
 
DIPJ: 59.9% 
(women) and 
54.5% (men) 
PIPJ: 34.9% 
(women( and 
33.7% (men) 
First CMCJ: 
41.2% 
(women) and 
49.9% (men)  
10 
years 
DIPJ: 6.0% (women) 
and 5.5% (men) 
PIPJ: 3.5% (women) 
and 3.4% (men) 
First CMCJ: 4.1% 
(women) and 5.0% 
(men) 
  
Kallman et al. 
(1990)23 
BLSA (study 
cohort), USA 
177 
 
Individuals 
aged <40 
years: 50% 
Individuals 
aged 40-59 
years: 50% 
Individuals 
aged ≥60 
years: 50% 
15.8 
years; 
12.4 
years; 
8.9 
years 
Individuals aged <40 
years: 3.2% 
Individuals aged 40-
59 years: 4.0% 
Individuals aged ≥60 
years: 5.6% 
Radiographic definition (without incorporation of incidence rate) 
Haugen et al. 
(2011) 20  
Framingham, 
USA 
464 
 
Women: 
96.4%  
Men: 91.4% 
Median 
8.7 
(IQR 
7.9-
9.5) 
years 
Women: 11.1% 
Men: 10.5% 
Güler-Yüksel et al. 
(2011)223 
GARP (study 
cohort), 
Netherlands 
181 
 
31.7% 2 years 15.9% 
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Hassett et al. 
(2006)255 
Chingford, 
UK 
Osteophytes: 222 
JSN: 308 
 
Osteophyte 
progression: 
72.5%;  
 
11 
years 
Osteophyte 
progression: 6.6% 
JSN progression: 
5.8% 
Plato et al. 
(1979)248 
BLSA (study 
cohort), USA 
29 
 
72.4% Mean 
13.45 
(range 
12-16) 
years 
5.4% 
MRI-based definition (with incorporation of incidence rate) 
Haugen et al. 
(2017)28 
Oslo, 
Norway 
69 
 
58.0% Mean 
4.7 (SD 
0.4) 
years 
12.3% 
 
Abbreviations: GARP, Genetics, Arthrosis and Progression; JSN, Joint space narrowing; OAI, Osteoarthritis Initiative; SD, Standard 
deviation; IQR, Interquartile range; DIPJ, Distal Interphalangeal Joints; PIPJ, Proximal Interphalangeal Joints; CMCJ, 
Carpometacarpal Joints; BLSA, Baltimore Longitudinal Study of Ageing; MRI, Magnetic Resonance Imaging. 
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TOC 
Hand osteoarthritis (OA) is a heterogeneous and prevalent condition involving multiple joints. In this 
Review, the authors provide an update on the epidemiology, presentation and burden of hand OA, as well 
as advances in imaging techniques, disease management and pathogenesis.  
